Show simple item record

dc.contributor.authorGomes, Fabio
dc.contributor.authorSerra-Bellver, Patricio
dc.contributor.authorLorigan, Paul C
dc.date.accessioned2018-02-01T15:29:40Z
dc.date.available2018-02-01T15:29:40Z
dc.date.issued2018-01-12
dc.identifier.citationThe role of nivolumab in melanoma. 2018 Future Oncolen
dc.identifier.issn1744-8301
dc.identifier.pmid29328782
dc.identifier.doi10.2217/fon-2017-0484
dc.identifier.urihttp://hdl.handle.net/10541/620801
dc.description.abstractThe incidence of melanoma continues to rise worldwide. Prior to 2010, there had been no progress in the treatment of advanced melanoma in living memory. Since then, immunotherapy has become a standard of care in the treatment of advanced melanoma. Nivolumab is a fully human monoclonal antibody against PD-1, which is a negative regulatory checkpoint in the T cells. The clinical benefit of nivolumab as a single agent is well established, with response rates of ≥40%, durable responses and a favorable tolerability profile. The combination of nivolumab and ipilimumab has also become a standard of care and the role of nivolumab in the adjuvant setting for high-risk patients has been recently confirmed.
dc.language.isoenen
dc.rightsArchived with thanks to Future oncology (London, England)en
dc.titleThe role of nivolumab in melanoma.en
dc.typeArticleen
dc.contributor.departmentThe Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalFuture Oncologyen
html.description.abstractThe incidence of melanoma continues to rise worldwide. Prior to 2010, there had been no progress in the treatment of advanced melanoma in living memory. Since then, immunotherapy has become a standard of care in the treatment of advanced melanoma. Nivolumab is a fully human monoclonal antibody against PD-1, which is a negative regulatory checkpoint in the T cells. The clinical benefit of nivolumab as a single agent is well established, with response rates of ≥40%, durable responses and a favorable tolerability profile. The combination of nivolumab and ipilimumab has also become a standard of care and the role of nivolumab in the adjuvant setting for high-risk patients has been recently confirmed.


This item appears in the following Collection(s)

Show simple item record